NEW YORK, NY--(Marketwire - September 24, 2007) - Consulting For Strategic Growth 1, Ltd. (CFSG), an investor and public relations firm specializing in domestic and international companies new to American financial markets, announced today that its CEO, Stanley Wunderlich, has agreed to provide personal consulting and strategic planning to China Aoxing Pharmaceutical Co. (OTCBB: CAXG).

China Aoxing is a China-based pharmaceutical company specializing in analgesics and pain management products. It is one of the first non-government entities to enter this largely untapped market in China. It is also one of a select few firms to be granted permission by China's SFCA (State Food and Drug Administration) to produce a number of leading generic analgesics, in some cases exclusively. On September 6, 2007, the Company announced it has received government approval to increase ownership of its main operating subsidiary providing it raises sufficient capital.

Over the next two months, Mr. Wunderlich will provide CAXG management with a detailed plan to increase their enterprise value. Broker/dealers who are interested to learn more about this company are invited to go to and click through for a detailed paid-for Red Chip research report. In addition, a PowerPoint presentation used at the recent UBS Global and Specialty Pharmaceutical conference will be available upon request.

CAXG management will be meeting with interested parties in and around the New York City area during October/November. Mr. Wunderlich is well known for his due diligence travels to China for previous China-based clients and for successfully bringing such companies to the attention of Wall Street investors.

About China Aoxing Pharmaceutical Group

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a pharmaceutical company in china which specializes in research, development, manufacturing and distribution of a variety of analgesics and pain management products. Its operating subsidiary, Hebei Aoxing Pharmaceutical Group Co. Ltd., is a corporation organized under the laws of the People's Republic of China. Hebei Aoxing is one of only a handful of companies in China to be granted the license to manufacture certain drugs, including Oxycodone, Pholcodine, Naloxone, and Tilidine, and is working closely with the Chinese government to assure availability throughout China.

About Consulting for Strategic Growth 1, Ltd.

CFSG has decades of hands-on corporate development experience combined with broad personal outreach in the private equity market and Wall Street broker/dealer communities. In the rapidly changing world of corporate finance, CFSG is a leader in reverse mergers, investor and public relations and corporate development for small-cap companies and private enterprises, both domestic and foreign. In addition to U.S. clients, the company's portfolio includes businesses based in such countries as China, South Africa and Canada. CFSG's long-term relations with investment bankers and private equity investors allow it to quickly position its clients in front of the decision makers, market makers and gatekeepers of the financial world. CFSG's strategic relationships include Rodman & Renshaw, Inc., a full-range investment bank nurturing emerging growth companies since 1951, and Wellfleet Partners, Inc., a boutique investment and merchant banking, venture capital and financial services and consulting firm founded in 1998.

Consulting For Strategic Growth 1, Ltd. ("CFSG1") provides consulting, business advisory, investor relations, public relations and corporate development services to public and private companies. In connection with these services, CFSG1 prepares press releases, corporate profiles, and other publications on behalf of and regarding its clients. Certain statements contained in this press release that are not purely historical are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "plans", "estimates", "could" and similar expressions that convey uncertainty of future events or outcomes identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of CFSG1 or its clients to differ materially from those expressed or implied by these forward-looking statements.

Contact Information: CONTACTS: Dan Stepanek Executive VP Consulting for Strategic Growth 1 Tel: 1-212-896-1202 Fax: 212-337-8089